Prognosis of men with penile metastasis and malignant priapism: a systematic review

Andrea Cocci _, Oliver W. Hakenberg, Tommaso Cai, Gabriella Nesi, Lorenzo Livi, Beatrice Detti, Andrea Minervini, Girolamo Morelli, Marco Carini, Sergio Serni and Mauro Gacci

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:2923-2930. https://doi.org/10.18632/oncotarget.23366

Metrics: PDF 2022 views  |   HTML 3688 views  |   ?  


Andrea Cocci1, Oliver W. Hakenberg2, Tommaso Cai3, Gabriella Nesi4, Lorenzo Livi4, Beatrice Detti4, Andrea Minervini1, Girolamo Morelli5, Marco Carini1, Sergio Serni1 and Mauro Gacci1

1Department of Urology, University of Florence, Florence, Italy

2Department of Urology, University Hospital Rostock, Rostock, Germany

3Department of Urology, Santa Chiara Hospital, Trento, Italy

4University of Florence, Florence, Italy

5Department of Urology, University of Pisa, Pisa, Italy

Correspondence to:

Andrea Cocci, email: [email protected]

Keywords: penis metastasis; penile metastasis; penile cancer; penis cancer

Abbreviations: MESH: Medical Subject Headings

Received: August 05, 2017    Accepted: September 04, 2017    Published: December 18, 2017


Introduction: Metastases to the penis are rare, but can have severe consequences. The aim of this study was to systematically review the literature in order to gain more information on the presentation and prognosis of this metastatic disease.

We reviewed the literature relating to all case reports, series and reviews about penile metastasis, from 2003 to 2013, through a Medline search. We identified 63 articles and 69 patients.

Metastases were located on the root (38.8%), the shaft (38.8%) or the glans (22.2%) of the penis. The diagnosis of penile metastasis was made after the primary cancer had been diagnosed. The most common presentation was a single small penile nodule. Ten patients reported priapism. The median survival time after diagnosis of penile metastasis was 10 months (range 6-18 months). A Kaplan-Meier analysis has shown that the patients presenting with priapism and those with metastases from non-urologic tumors have a significantly worse prognosis (age adjusted Log Rank: p=0.037 for priapism vs. no priapism and p=0.045 for urologic vs. non urologic).

There are prognostic differences based on the presentation of penile metastases. Survival is substantial and treatment should therefore take into account symptoms improvement and quality of life.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23366